Podcasts about therapeutics

We love to hear from our listeners. Send us a message. On this week's episode of the Business of Biotech, Dan Schmitt, President and CEO at Actuate Therapeutics, talks about building a company around elraglusib, a GSK-3β inhibitor for cancer. Dan describes his fast-fail approach to early product testing and development, using basket trials to evaluate chemotherapy combinations, and choosing pancreatic cancer as a lead program. He also talks about surviving an IPO during a brutal funding cycle for biotech, building lean teams and efficient operations, and potentially onshoring API in response to changing U.S. policy. Access this and hundreds of episodes of the Business of Biotech videocast under the Business of Biotech tab at lifescienceleader.com. Subscribe to our monthly Business of Biotech newsletter. Get in touch with guest and topic suggestions: ben.comer@lifescienceleader.comFind Ben Comer on LinkedIn: https://www.linkedin.com/in/bencomer/

Did you know that a single crumb of bread is enough to cause an autoimmune response in children with celiac disease? Dr. Pankaj Vohra, Professor of Pediatrics and Board-Certified Pediatric Gastroenterologist, joins medical student Andrea Smith to discuss the evaluation and management of celiac disease, as well as essential guidance for following a gluten-free diet. Specifically, they will: Review the epidemiology of celiac disease and identify common symptoms and presentations of celiac disease Describe the pathophysiology of celiac disease including histopathological changes to the duodenum Identify diagnostic tests and criteria for diagnosing celiac disease in the pediatric population Identify common sources of gluten and the basics of identifying gluten on food labels Discuss typical management of celiac disease including appropriate screening tests and managing accidental gluten ingestion Special thanks to Dr. Rebecca Yang and Dr. Neeharika Bade for peer reviewing this episode. CME available free with sign up: Link coming soon! References: Bolia, R., & Thapar, N. (2023). Celiac Disease in Children: A 2023 Update. In Indian Journal of Pediatrics. Springer. https://doi.org/10.1007/s12098-023-04659-w Gidrewicz, D., Potter, K., Trevenen, C. L., Lyon, M., & Butzner, J. D. (2015). Evaluation of the ESPGHAN celiac guidelines in a North American pediatric population. American Journal of Gastroenterology, 110(5), 760–767. https://doi.org/10.1038/ajg.2015.87 Hill, I. D., Fasano, A., Guandalini, S., Hoffenberg, E., Levy, J., Reilly, N., & Verma, R. (2016). NASPGHAN clinical report on the diagnosis and treatment of gluten-related disorders. Journal of Pediatric Gastroenterology and Nutrition, 63(1), 156–165. https://doi.org/10.1097/MPG.0000000000001216 Husby, S., Koletzko, S., Korponay-Szabó, I., Kurppa, K., Mearin, M. L., Ribes-Koninckx, C., Shamir, R., Troncone, R., Auricchio, R., Castillejo, G., Christensen, R., Dolinsek, J., Gillett, P., Hróbjartsson, A., Koltai, T., Maki, M., Nielsen, S. M., Popp, A., Størdal, K., … Wessels, M. (2020). European Society Paediatric Gastroenterology, Hepatology and Nutrition Guidelines for Diagnosing Coeliac Disease 2020. In Journal of Pediatric Gastroenterology and Nutrition (Vol. 70, Issue 1, pp. 141–156). Lippincott Williams and Wilkins. https://doi.org/10.1097/MPG.0000000000002497 Nenna, R., Tiberti, C., Petrarca, L., Lucantoni, F., Mennini, M., Luparia, R. P. L., Panimolle, F., Mastrogiorgio, G., Pietropaoli, N., Magliocca, F. M., & Bonamico, M. (2013). The celiac iceberg: Characterization of the disease in primary schoolchildren. Journal of Pediatric Gastroenterology and Nutrition, 56(4), 416–421. https://doi.org/10.1097/MPG.0b013e31827b7f64 Sahin, Y. (2021). Celiac disease in children: A review of the literature. In World Journal of Clinical Pediatrics (Vol. 10, Issue 4, pp. 53–71). Baishideng Publishing Group Co. https://doi.org/10.5409/wjcp.v10.i4.53 Salden, B. N., Monserrat, V., Troost, F. J., Bruins, M. J., Edens, L., Bartholomé, R., Haenen, G. R., Winkens, B., Koning, F., & Masclee, A. A. (2015). Randomised clinical study: Aspergillus niger-derived enzyme digests gluten in the stomach of healthy volunteers. Alimentary Pharmacology and Therapeutics, 42(3), 273–285. https://doi.org/10.1111/apt.13266 Schuppan, D., Mäki, M., Lundin, K. E. A., Isola, J., Friesing-Sosnik, T., Taavela, J., Popp, A., Koskenpato, J., Langhorst, J., Hovde, Ø., Lähdeaho, M.-L., Fusco, S., Schumann, M., Török, H. P., Kupcinskas, J., Zopf, Y., Lohse, A. W., Scheinin, M., Kull, K., … Greinwald, R. (2021). A Randomized Trial of a Transglutaminase 2 Inhibitor for Celiac Disease. New England Journal of Medicine, 385(1), 35–45. https://doi.org/10.1056/nejmoa2032441 Tack, G. J., van de Water, J. M. W., Bruins, M. J., Kooy-Winkelaar, E. M. C., van Bergen, J., Bonnet, P., Vreugdenhil, A. C. E., Korponay-Szabo, I., Edens, L., von Blomberg, B. M. E., Schreurs, M. W. J., Mulder, C. J., & Koning, F. (2013). Consumption of gluten with gluten-degrading enzyme by celiac patients: A pilot-study. World Journal of Gastroenterology, 19(35), 5837–5847. https://doi.org/10.3748/wjg.v19.i35.5837 Husby S, Koletzko S, Korponay-Szabó IR, et al. European Society for Pediatric Gastroenterology, Hepatology, and Nutrition guidelines for the diagnosis of coeliac disease. J Pediatr Gastroenterol Nutr 2012; 54: 136–160

Welcome to the Psychedelic Conversations Podcast!In this episode, we discuss the emerging frontier of psychedelic-assisted neurorehabilitation with clinical neurologist Burton Tabaac. We explore his path into psychedelic science, his work with Johns Hopkins University, and the groundbreaking Fathom Trial—a study investigating whether psilocybin, paired with enriched, non-task-based play, can reopen critical periods of neuroplasticity to support stroke recovery far beyond the traditional healing window. We also dive into the legal and regulatory challenges of Schedule I substances, the evolving balance between clinical and ceremonial approaches, and the importance of honoring indigenous lineages while expanding patient access. Together, we reflect on the art of medicine, the role of set and setting, and the hopeful future of psychedelics in neurological healing.About Burton:Dr. Burton J. Tabaac, MD, FAHA, brings a wealth of expertise in neurology and stroke rehabilitation to Rose Hill. As an Associate Professor and Section Chief of Neurology at The University of Nevada's Reno School of Medicine, and Medical Director of Stroke at Carson Tahoe Health, Dr. Tabaac has been at the forefront of innovative neurological treatments. A graduate of the prestigious cerebrovascular neurology fellowship program at The Johns Hopkins University Hospital, Dr. Tabaac's accolades include being a three-time recipient of The Arnold P. Gold Foundation's Humanism and Excellence in Teaching Award and induction into the Alpha Omega Alpha Honor Medical Society. He recently published an eight-part paper in the American Journal of Therapeutics reviewing psychedelics as therapeutics for primary care clinicians. Dr. Tabaac's groundbreaking research focuses on the application of psychedelics in brain injury and stroke rehabilitation. Dr. Tabaac was recently appointed by the Governor of Nevada to serve as a member of the state's Psychedelic Medicines Working Group, which provides expertise and testimony relating to the therapeutic use of entheogens. As the host of The Zero Hour Podcast, he engages with leading experts in psychedelic research. His commitment to advancing the field was further highlighted in his 2022 TEDx talk at UCLA, “Mental Health Meets Psychedelics.”Connect with Burton:- Website: https://rosehill.life/- Twitter: https://x.com/burtontabaac?lang=en- LinkedIn: https://www.linkedin.com/in/burtontabaacThank you so much for joining us! Psychedelic Conversations Podcast is designed to educate, inform, and expand awareness.For more information, please head over to https://www.psychedelicconversations.comPlease share with your friends or leave a review so that we can reach more people and feel free to join us in our private Facebook group to keep the conversation going. https://www.facebook.com/groups/psychedelicconversationsThis show is for information purposes only, and is not intended to provide mental health or medical advice.About Susan Guner:Susan Guner is a holistic psychotherapist with a mindfulness-based approach grounded in Transpersonal Psychology, focusing on trauma-informed, community-centric processes that offer a broader understanding of human potential and well-being.Connect with Susan:Website: https://www.psychedelicconversations.com/Facebook: http://www.facebook.com/susan.gunerLinkedIn: https://www.linkedin.com/in/susan-guner/Instagram: http://www.instagram.com/susangunerTwitter: http://www.twitter.com/susangunerBlog: https://susanguner.medium.com/Podcast: https://anchor.fm/susan-guner#PsychedelicConversations #SusanGuner #BurtonTabaac #PsychedelicPodcast #Microdosing #PsychedelicScience

Drs. Camacho and Lewiecki discuss emerging osteoporosis therapies that are revolutionizing bone health treatment, with promising developments like oral parathyroid hormone medications and dual-action anabolic agents that challenge traditional injection-based approaches. Biosimilars, particularly for denosumab, are expanding patient access by offering highly similar, potentially more affordable alternatives to brand-name drugs, signaling a transformative era in osteoporosis care.

On this episode of Big Biz Show, Kirk Huntsman, CEO of Vivos Therapeutics, discusses their pivot to acquiring medical sleep practices and testing centers and the subsequent growth of their business. Jack Lu of Ainos joins us to talk about the last frontier of AI's healthcare revolution–the sense of smell. We're also joined by friends of the show, Shep Hyken and Dan Negroni.

Sully, Mike Costa and Mary Burt-Godwin host a jam-packed show today with Corey Perlman of Impact Social Media talking about social media trends that businesses need to know about and Patrick DeHaan of Gas Buddy sharing the latest in gas price trends around the country. The show also features Jim Joyce of Sigyn Therapeutics and David Garofalo of Gold Royalty Corp.

Michael Cloonan, CEO of Sionna Therapeutics, shares his insights about leadership in biopharma and how Sionna is working to restore the cystic fibrosis transmembrane conductance regulator for people living with cystic fibrosis.

It is well known that inside nearly every living cell on this planet, there are instructions powering the dynamics of everything in the cell, known as deoxyribonucleic acid (DNA). Enoch Yeung, Associate Professor of Mechanical Engineering at UC, Santa Barbara, explains how DNA is the genetic code that tells cells where to live, how to live, and how to adapt when things get tough. Editing DNA has unlocked new potential in biology, enabled new therapeutics, diagnostics, and modes of treating diseases. Since DNA is double-stranded, it literally maintains a backup copy of itself to proof-read and facilitate stability of code. The double-stranded nature of DNA also means it can sometimes encode two messages in a given length! In short, DNA is amazing. Series: "GRIT Talks" [Science] [Show ID: 41040]

It is well known that inside nearly every living cell on this planet, there are instructions powering the dynamics of everything in the cell, known as deoxyribonucleic acid (DNA). Enoch Yeung, Associate Professor of Mechanical Engineering at UC, Santa Barbara, explains how DNA is the genetic code that tells cells where to live, how to live, and how to adapt when things get tough. Editing DNA has unlocked new potential in biology, enabled new therapeutics, diagnostics, and modes of treating diseases. Since DNA is double-stranded, it literally maintains a backup copy of itself to proof-read and facilitate stability of code. The double-stranded nature of DNA also means it can sometimes encode two messages in a given length! In short, DNA is amazing. Series: "GRIT Talks" [Science] [Show ID: 41040]

It is well known that inside nearly every living cell on this planet, there are instructions powering the dynamics of everything in the cell, known as deoxyribonucleic acid (DNA). Enoch Yeung, Associate Professor of Mechanical Engineering at UC, Santa Barbara, explains how DNA is the genetic code that tells cells where to live, how to live, and how to adapt when things get tough. Editing DNA has unlocked new potential in biology, enabled new therapeutics, diagnostics, and modes of treating diseases. Since DNA is double-stranded, it literally maintains a backup copy of itself to proof-read and facilitate stability of code. The double-stranded nature of DNA also means it can sometimes encode two messages in a given length! In short, DNA is amazing. Series: "GRIT Talks" [Science] [Show ID: 41040]

It is well known that inside nearly every living cell on this planet, there are instructions powering the dynamics of everything in the cell, known as deoxyribonucleic acid (DNA). Enoch Yeung, Associate Professor of Mechanical Engineering at UC, Santa Barbara, explains how DNA is the genetic code that tells cells where to live, how to live, and how to adapt when things get tough. Editing DNA has unlocked new potential in biology, enabled new therapeutics, diagnostics, and modes of treating diseases. Since DNA is double-stranded, it literally maintains a backup copy of itself to proof-read and facilitate stability of code. The double-stranded nature of DNA also means it can sometimes encode two messages in a given length! In short, DNA is amazing. Series: "GRIT Talks" [Science] [Show ID: 41040]

It is well known that inside nearly every living cell on this planet, there are instructions powering the dynamics of everything in the cell, known as deoxyribonucleic acid (DNA). Enoch Yeung, Associate Professor of Mechanical Engineering at UC, Santa Barbara, explains how DNA is the genetic code that tells cells where to live, how to live, and how to adapt when things get tough. Editing DNA has unlocked new potential in biology, enabled new therapeutics, diagnostics, and modes of treating diseases. Since DNA is double-stranded, it literally maintains a backup copy of itself to proof-read and facilitate stability of code. The double-stranded nature of DNA also means it can sometimes encode two messages in a given length! In short, DNA is amazing. Series: "GRIT Talks" [Science] [Show ID: 41040]

Send us a textThijs Spoor is Chief Executive Officer at Perspective Therapeutics ( https://perspectivetherapeutics.com/ ), a clinical-stage, radiopharmaceutical company that is pioneering innovative treatments for cancers. The Company's proprietary technology utilizes the alpha emitting isotope Pb-212 to deliver powerful radiation directly to cancer cells via high-affinity targeting peptides.Prior to this, Thijs was the Chairman at Verifi H2O. Thijs also held the position of Chief Executive Officer at Viewpoint Molecular Targeting, Inc. and KBP BioSciences.Thijs also has served as CEO at AzurRx BioPharma, where they focused on developing targeted therapies for gastrointestinal diseases, and CEO at FluoroPharma, a company focused on the discovery, development, and commercialization novel molecular positron emission tomography (PET) agents for the cardiovascular, oncology and neurology arenas.Thijs also worked as a Strategy Consultant at Oliver Wyman, a Biotechnology Analyst at J.P. Morgan, and a Medical Devices Analyst at Credit Suisse. Thijs began their career at GE Healthcare, where he served as the Director of Strategic Marketing and played a key role in reshaping the company's strategic directions in various areas.Thijs completed his Bachelor of Science in Pharmacy from the University of Toronto and an MBA in Finance from Columbia Business School.#ThijsSpoor #PerspectiveTherapeutics #Radiopharmaceuticals #NuclearMedicine #Cancer #Oncology #AlphaEmittingIsotopes #AlphaParticles #BetaParticles #Radiation #Lead #Pb212 #Lutetium #Actinium #CellTargetingPeptide #Chelator #Linker #NeuroendocrineTumors #SomatostatinReceptorSubtype2 #Melanoma #Theranostic #ProgressPotentialAndPossibilities #IraPastor #Podcast #Podcaster #ViralPodcast #STEM #Innovation #Technology #Science #ResearchSupport the show

In this week's episode, Blood editor Dr. Laura Michaelis interviews authors Drs. Terri Parker and Peter Lenting on their latest papers published in Blood Journal. Dr. Lenting discusses his work on introducing a new therapeutic approach to von Willebrand disease with the development of a novel bispecific antibody (KB-V13A12) that links endogenous mouse VWF to albumin, extending VWF half-life twofold with cessation of provoked bleeding. Dr Parker shares the results of a 43-patient phase 2 study that evaluates the single agent isatuximab, a CD38 monoclonal antibody, in patients with relapsed/refractory AL amyloidosis. With a hematological response rate of 77%, organ response rates between 50 and 57%, and an excellent safety profile, the current study lays the foundation for future use of isatuximab across treatment settings and combination strategies.Featured ArticlesIsatuximab for Relapsed and/or Refractory AL Amyloidosis: Results of a Prospective Phase 2 Trial (SWOG S1702)A bispecific nanobody for the treatment of von Willebrand disease type 1

Send us a textBen Zimmer is CEO of Priovant Therapeutics ( https://www.priovanttx.com/ ), a clinical-stage biotechnology company focused on delivering novel therapies for autoimmune diseases associated with the greatest morbidity and mortality. Priovant is developing oral brepocitinib, a potential first-in-class dual inhibitor of TYK2 and JAK1, across multiple severe autoimmune indications, unlocking new treatment options for patients who are underserved by existing therapies.Ben joined Priovant from Roivant, where he was a member of the founding team in early 2015 and held multiple leadership roles across the organization, including President, Roivant Health, Chief Operating Officer, and Head, Public Affairs. As President, Roivant Health, Ben led and oversaw the launch of Roivant's Chinese biopharmaceutical subsidiaries, healthcare technology companies (including Datavant), and computationally powered drug discovery platform (including VantAI). Earlier in his career, Ben was a consultant at McKinsey & Co and co-founded and led a public policy non-profit. He holds a BA magna cum laude from Harvard College and a JD from Yale Law School.#BenZimmer #PriovantTherapeutics #AutoimmuneDiseases #Brepocitinib #TYK2 #JAK1 #Dermatomyositis #NonInfectiousUveitis #Pfizer #Roivant #VivekRamaswamy #ProgressPotentialAndPossibilities #IraPastor #Podcast #Podcaster #STEM #Innovation #Technology #Science #ResearchSupport the show

Aging quietly shapes everything - our economies, our politics, our families, and the horizon of what nations can become. Jacob and longevity expert Dylan Livingston, founder of the Alliance for Longevity Initiatives (A4LI), take a dive into the emerging science that treats aging not as fate, but as a solvable biological problem with staggering geopolitical consequences. The two explore how extending healthy human life could transform productivity, rebalance global power, upend healthcare economics, and challenge long-held assumptions about decline. At its core is a question: what happens when longevity becomes a public policy frontier, not a personal fantasy?--Timestamps:(00:00) - Introduction(00:21) - The Importance of Longevity(02:48) - Personal Journey into Longevity(04:48) - Historical Quest for Immortality(10:02) - Modern Longevity Science(13:13) - Challenges and Societal Implications(19:53) - A4LI's Mission and Achievements(27:38) - Policy and Future Goals(32:51) - FDA Guidance and Incentives for Therapeutics(34:01) - Supply Chain Concerns and American Manufacturing(35:32) - Political Perspectives on Longevity(37:13) - Bipartisan Efforts and Advocacy(41:55) - Challenges and Opportunities in Longevity Research(52:28) - Economic and Demographic Implications of Longevity(01:01:45) - Closing Remarks and Future Conversations--Referenced in the Show:A4LI - https://a4li.org/ --Jacob Shapiro Site: jacobshapiro.comJacob Shapiro LinkedIn: linkedin.com/in/jacob-l-s-a9337416Jacob Twitter: x.com/JacobShapJacob Shapiro Substack: jashap.substack.com/subscribe --The Jacob Shapiro Show is produced and edited by Audiographies LLC. More information at audiographies.com --Jacob Shapiro is a speaker, consultant, author, and researcher covering global politics and affairs, economics, markets, technology, history, and culture. He speaks to audiences of all sizes around the world, helps global multinationals make strategic decisions about political risks and opportunities, and works directly with investors to grow and protect their assets in today's volatile global environment. His insights help audiences across industries like finance, agriculture, and energy make sense of the world.--

Invité :Stéphane Roulon, Président et cofondateur de MB TherapeuticsHébergé par Audiomeans. Visitez audiomeans.fr/politique-de-confidentialite pour plus d'informations.

Is there a future where we will manufacture entire organs? If that's the case, it's not tomorrow. Yet, the era of regenerative medicine and tissue engineering is very much real and happening now! In some fields, like in dentistry, we are already 3D printing implants that are placed in patients' mouths. In others, like in orthopedic or plastic surgery, cells are harvested from patients to be modified and placed back into their bodies. But what we can't do yet is create complex, functional tissue constructs that can actively remodel and integrate with the human body to restore physiological function. This is the challenge that Simon Mackenzie and his team at Cellbricks Therapeutics are striving to overcome. The technology they have developed is fascinating, sitting at the crossroads of biomaterials, cellular engineering, and 3D printing. A discipline that aims to create the first "tissue therapeutics." The prospects it opens up are incredible: building grafts to heal complex wounds, functional implants for the liver, pancreatic islets for insulin production, and much more! In this episode, we explore the inner workings of this fascinating field and the road ahead before the first tissue therapeutics are used routinely in the clinic, from a technical and regulatory perspective. A thought-provoking conversation offering a glimpse into what a truly "regenerative" medicine could look like in the future! Timeline: 00:00:00 - Simon's background as a Biochemist and seasoned executive in the life sciences industry 00:08:28 - Defining bioprinting, biofabrication, and tissue therapeutics 00:12:56 - Cellbricks' mission to recover tissue loss thanks to engineered tissue therapeutics 00:20:52 - Current evidence on the therapeutic potential of biofabricated tissues 00:24:55 - Cellbricks' biofabrication platform to engineer living tissues 00:30:33 - The challenges around the transport of biofabricated tissues 00:35:36 - The path toward broad use of biofabricated tissues in medicine What we also talked about with Simon: Erik Gatenholm Cellink BICO Aspect Biosystems Daniela Marino Cutiss Organoids L'Oréal Lisa Anderson Paragonix Technologies As suggested by Simon during the episode, you can learn more about biofabrication and tissue engineering on the Advanced Regenerative Manufacturing Institute website. You can get in touch with Simon via LinkedIn, and follow Cellbricks Therapeutics' activities on their website, and LinkedIn. ✉️ If you want to give me feedback on the episode or suggest potential guests, contact me over LinkedIn or via email! ⭐️ And if you liked the episode, please share it, subscribe to the podcast, and leave a 5-star review on streaming platforms!

Invité :Stéphane Roulon, Président et cofondateur de MB TherapeuticsHébergé par Audiomeans. Visitez audiomeans.fr/politique-de-confidentialite pour plus d'informations.

Now in its second season, this exclusive CNS Summit podcast series features biopharma leaders sharing bold ideas, breakthrough innovations and what it takes to move smarter and faster for patients. How is a mid-sized, family-owned company scaling with impact in specialty neurology? Stefan König, CEO of Merz Therapeutics, joins guest host Andy Moniz, VP of Therapeutic Strategy and Innovation at Syneos Health at the 2025 CNS Summit. Together, they explore what it takes to lead through volatility, invest globally and grow with intention, all while upholding culture and delivering with purpose. In this episode: How Merz is leveraging global capital to expand its neurology pipeline What today's market volatility reveals about opportunity Why “balanced disruption” matters for scaling innovation The views expressed in this podcast belong solely to the speakers and do not represent those of their organization. If you want access to more future-focused, actionable insights to help biopharmaceutical companies better execute and succeed in a constantly evolving environment, visit the Syneos Health Insights Hub. The perspectives you'll find there are driven by dynamic research and crafted by subject matter experts focused on real answers to help guide decision-making and investment. You can find it all at https://www.syneoshealth.com/insights-hub. Like what you're hearing? Be sure to rate and review us! We want to hear from you! If there's a topic you'd like us to cover on a future episode, contact us at podcast@syneoshealth.com.

Andrew Rosen, Chief Executive Officer of the National Ataxia Foundation, has a dual mission of accelerating research for treatments and cures for Ataxia while supporting the patients affected by this rare disease. Ataxia describes both a group of hereditary genetic diseases and symptoms of lack of coordination seen in other conditions.  While genetic tests exist for hereditary Ataxia, a significant challenge in drug development has been the lack of a reliable biomarker. To encourage drug development, NAF has funded translational research and the world's most extensive study for SCAs, Spinocerebellar Ataxias, providing new data on the progression of the disease and for the design of future trials. Andrew explains, "NAF has been around for a long time. We were founded in the late 1950s by a neurologist in western Minnesota who had a disease called Ataxia in his family. And NAF's mission has really been twofold ever since that. Our formal statement is that we are trying to accelerate the development of treatments and a cure while working to improve the lives of those living with Ataxia. And so we really focus on research and support. We do a lot in the research world. We fund grants for researchers who are looking into the various types of Ataxia. You'd be hard pressed to find an Ataxia researcher in the world, I think I can say now at this point that hasn't received a grant from NAF at one time or another in their career. We also do a lot of translational-type research. We fund the largest natural history study in Ataxias."   "So, the term ataxia itself is even complex because it both describes a genetic disease, and I think of that as capital 'A' - Ataxia, but it's also a symptom of many other conditions. So small 'a', if you will. Ataxia just means a lack of coordination. It comes from a Greek word. And so what I mean by both hereditary and other things is if you, for instance, have too much to drink, you would show signs of Ataxia. You might stumble when you walk, and your speech might be slurred. Those are the two classic symptoms of hereditary Ataxia. Right. So that's really the Ataxias that we at NAF focus on. So hereditary, as in passed from parent to child, there are several hundred forms of hereditary Ataxia, and they continue to find more as more specific genetic mutations are discovered year after year now."  #NationalAtaxiaFoundation #Ataxia #PatientAdvocacy #RareDisease #SCA ataxia.org Download the transcript here

Andrew Rosen, Chief Executive Officer of the National Ataxia Foundation, has a dual mission of accelerating research for treatments and cures for Ataxia while supporting the patients affected by this rare disease. Ataxia describes both a group of hereditary genetic diseases and symptoms of lack of coordination seen in other conditions.  While genetic tests exist for hereditary Ataxia, a significant challenge in drug development has been the lack of a reliable biomarker. To encourage drug development, NAF has funded translational research and the world's most extensive study for SCAs, Spinocerebellar Ataxias, providing new data on the progression of the disease and for the design of future trials. Andrew explains, "NAF has been around for a long time. We were founded in the late 1950s by a neurologist in western Minnesota who had a disease called Ataxia in his family. And NAF's mission has really been twofold ever since that. Our formal statement is that we are trying to accelerate the development of treatments and a cure while working to improve the lives of those living with Ataxia. And so we really focus on research and support. We do a lot in the research world. We fund grants for researchers who are looking into the various types of Ataxia. You'd be hard pressed to find an Ataxia researcher in the world, I think I can say now at this point that hasn't received a grant from NAF at one time or another in their career. We also do a lot of translational-type research. We fund the largest natural history study in Ataxias."   "So, the term ataxia itself is even complex because it both describes a genetic disease, and I think of that as capital 'A' - Ataxia, but it's also a symptom of many other conditions. So small 'a', if you will. Ataxia just means a lack of coordination. It comes from a Greek word. And so what I mean by both hereditary and other things is if you, for instance, have too much to drink, you would show signs of Ataxia. You might stumble when you walk, and your speech might be slurred. Those are the two classic symptoms of hereditary Ataxia. Right. So that's really the Ataxias that we at NAF focus on. So hereditary, as in passed from parent to child, there are several hundred forms of hereditary Ataxia, and they continue to find more as more specific genetic mutations are discovered year after year now."  #NationalAtaxiaFoundation #Ataxia #PatientAdvocacy #RareDisease #SCA ataxia.org Listen to the podcast here

In this episode, Steven Ringel, CEO of the Kazuna Foundation and Nome Therapeutics, joins the podcast to discuss how his team is using artificial intelligence to make personalized medicine accessible for rare disease patients. 

Dave and Brandon talk about Q3 earnings. Plus Brandon dissects the financial ratio that many analysts believe to be the most important financial ratio on Wall Street and Dave share's a listeners option strategy.

In this episode, Steven Ringel, CEO of the Kazuna Foundation and Nome Therapeutics, joins the podcast to discuss how his team is using artificial intelligence to make personalized medicine accessible for rare disease patients. 

For the first time in human history, we can diagnose thousands of genetic diseases—often for under $1,000—but we still can't treat most of them. The problem isn't understanding what's broken; it's delivering the fix to the right cells.Eric Kelsic, CEO of Dyno Therapeutics, joins a16z's Jorge Conde to explain how AI-designed protein shells are solving gene therapy's delivery crisis. They explore why Huntington's patients can now get 15 extra years of healthy life, how Dyno inverted the liver-to-brain delivery ratio by 1000x, and why capsids evolved by nature are now being designed by machine learning models trained on millions of variants.Eric introduces the concept of genetic agency—humanity's first-ever ability to take action at the DNA level—and details why solving delivery for common diseases will make ultra-rare disease treatments economically viable. Plus: what happens when gene therapy requires neurosurgery today but could be a simple injection tomorrow, why recent deaths in clinical trials prove we need better technology now, and how genetic medicine could become as routine as surgery within our lifetimes. Resources:Follow Eric on X: https://x.com/ekelsicFollow Jorge on X: https://x.com/JorgeCondeBioLearn more about GATC 2025: https://www.dynotx.com/gatc2025 Stay Updated:If you enjoyed this episode, be sure to like, subscribe, and share with your friends!Find a16z on X: https://x.com/a16zFind a16z on LinkedIn: https://www.linkedin.com/company/a16zListen to the a16z Podcast on Spotify: https://open.spotify.com/show/5bC65RDvs3oxnLyqqvkUYXListen to the a16z Podcast on Apple Podcasts: https://podcasts.apple.com/us/podcast/a16z-podcast/id842818711Follow our host: https://x.com/eriktorenbergPlease note that the content here is for informational purposes only; should NOT be taken as legal, business, tax, or investment advice or be used to evaluate any investment or security; and is not directed at any investors or potential investors in any a16z fund. a16z and its affiliates may maintain investments in the companies discussed. For more details please see a16z.com/disclosures.  Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Send us a textIn this episode of WTR Small-Cap Spotlight, Anthony Tennyson, CEO and Co-Founder of Solvonis Therapeutics (LSE: SVNS | OTC: SLVNF), joins host Tim Gerdeman, Vice Chair and Co-Founder of Water Tower Research, and analyst Robert Sassoon to discuss the company's mission to transform care for addiction and mental health disorders.Tennyson shares Solvonis' journey from inception to its Phase 3 lead program for alcohol use disorder (AUD), which achieved 86% patient sobriety in prior Phase 2 trials, and details how the company's **dual R&D strategy—repurposing existing molecules and discovering new small molecules—**has allowed it to progress with exceptional capital efficiency. The discussion also covers the SVN-001 and SVN-002 programs, commercialization strategy, and Solvonis' strong financial position and runway through 2027 as it works toward redefining treatment for one of the world's most pervasive unmet medical needs.

In this episode of Cannabinoid Connect, host Kevin Carrillo sits down with Brendan McKee, Co-Founder and COO of Silver Therapeutics — a cannabis retailer that has grown from a single dispensary in Massachusetts to a multi-state operation with locations across the Northeast. Brendan shares: His founder journey — from pro athlete to cannabis entrepreneur Lessons from launching one of the first adult-use dispensaries on the East Coast How Silver Therapeutics scaled exceptional customer service across states The evolving retail landscape: from $400 ounces to market saturation Smart growth strategies, local sourcing, and community-focused retail Navigating complex regulatory frameworks in each state His outlook on federal legalization, distressed assets, and acquisitions

We love to hear from our listeners. Send us a message. On this week's episode of the Business of Biotech, we're speaking with Bernard Ravina, M.D., CEO at Vima Therapeutics, a company that emerged from stealth in May with $60 million Series A financing to develop an oral candidate for dystonia, a movement disorder. Ravina talks about transitioning from government and academic medicine to industry, partnering with Atlas Ventures and defining the company's thesis, the reasons behind working in stealth mode and when to emerge, and the clinical plan and potential for VIM0423.  Access this and hundreds of episodes of the Business of Biotech videocast under the Business of Biotech tab at lifescienceleader.com. Subscribe to our monthly Business of Biotech newsletter. Get in touch with guest and topic suggestions: ben.comer@lifescienceleader.comFind Ben Comer on LinkedIn: https://www.linkedin.com/in/bencomer/

 Confused About Hormones or HRT? Dr. Nicole Lovat Helps You Navigate Midlife Health with Confidence and Clarity  Midlife health is not one-size-fits-all — and “normal” doesn't always mean optimal. When you understand your hormones, you can advocate for care that helps you feel your best — inside and out. 

Dr. Yuri Maricich, Chief Medical Officer at CAMP4 Therapeutics, describes regulatory RNA, a new area of biology that recognizes the role of Reg RNA in the production of proteins from specific genes. This technology is well-suited for haploinsufficient diseases such as SYNGAP1-related disorders, in which there is a lack of healthy protein and both parents carry a copy of the mutated gene. The goal is to create disease-modifying treatments that correct the underlying genetic cause rather than treating the symptoms. Yuri explains, "What was really unique about CAMP4's scientific approach is that we're focused on a whole new and emerging area of biology called regulatory RNA. And these are control elements for the expression of genes. In other words, how much protein we get from a particular gene. And there's been a lot of work in the past on how to have less protein made, particularly if it's a protein that has a mutation that causes a problem. But in medicine, there have been very few opportunities to actually increase the amount of protein, but there are many diseases that need more healthy protein." "The backdrop of CAMP4 is that there was work done just over eight years ago at the Whitehead Institute at the Massachusetts Institute of Technology in a lab by Rick Young, and he was working with a colleague at Boston Children's Hospital, Lenson, and they noticed that there was this group of so-called regRNAs. These were non-coding regions that historically have been really ignored. And as they looked and explored their function further, what they discovered was that, in fact, these regRNA elements play a critical role in controlling how much protein is produced. And so the story of CAMP4 has been to continue to understand and map different cell lines so that we could take a particular target gene and, by using tools or established medicines, for example, like antisense oligonucleotides, we could actually increase the amount of a gene's protein back up to normal." #CAMP4 #CAMP4Therapeutics #SYNGAP1 #CuresSYNGAP1 #regRNA #RegulatoryRNA camp4tx.com Download the transcript here

Dr. Yuri Maricich, Chief Medical Officer at CAMP4 Therapeutics, describes regulatory RNA, a new area of biology that recognizes the role of Reg RNA in the production of proteins from specific genes. This technology is well-suited for haploinsufficient diseases such as SYNGAP1-related disorders, in which there is a lack of healthy protein and both parents carry a copy of the mutated gene. The goal is to create disease-modifying treatments that correct the underlying genetic cause rather than treating the symptoms. Yuri explains, "What was really unique about CAMP4's scientific approach is that we're focused on a whole new and emerging area of biology called regulatory RNA. And these are control elements for the expression of genes. In other words, how much protein we get from a particular gene. And there's been a lot of work in the past on how to have less protein made, particularly if it's a protein that has a mutation that causes a problem. But in medicine, there have been very few opportunities to actually increase the amount of protein, but there are many diseases that need more healthy protein." "The backdrop of CAMP4 is that there was work done just over eight years ago at the Whitehead Institute at the Massachusetts Institute of Technology in a lab by Rick Young, and he was working with a colleague at Boston Children's Hospital, Lenson, and they noticed that there was this group of so-called regRNAs. These were non-coding regions that historically have been really ignored. And as they looked and explored their function further, what they discovered was that, in fact, these regRNA elements play a critical role in controlling how much protein is produced. And so the story of CAMP4 has been to continue to understand and map different cell lines so that we could take a particular target gene and, by using tools or established medicines, for example, like antisense oligonucleotides, we could actually increase the amount of a gene's protein back up to normal." #CAMP4 #CAMP4Therapeutics #SYNGAP1 #CuresSYNGAP1 #regRNA #RegulatoryRNA camp4tx.com Listen to the podcast here

Permission to Feel: Creating Safety for Emotional Intimacy Episode Summary In this powerful episode, Dr. Kevin Skinner and MaryAnn Michaelis explore one of the most important — and misunderstood — aspects of healing after betrayal: emotional experience and expression. Many of us have been conditioned to suppress emotions, especially those that feel scary, overwhelming, or “unacceptable” — such as anger, fear, grief, or shame. Often, our logic steps in and says, “You shouldn't feel that,”creating an internal shut-down that prevents emotional processing and healing. Drawing on neuroscience, attachment theory, and therapeutic insights, Dr. Skinner and MaryAnn discuss: Why we feel before we think — and what that means for trauma responses The cultural discomfort with strong emotions and how this affects relationships How betrayal trauma conditions many partners to distrust their internal emotional cues The science of tears — and how crying releases different emotional chemicals Jill Bolte Taylor's “Brain Huddle” — an integrated approach to emotional awareness How emotional safety enables true relational intimacy Why our job is not to fix emotions, but to be with the person experiencing them What prevents couples from sharing emotions — and how to rebuild that trust Listeners are invited to approach their inner world with curiosity instead of judgment, give themselves permission to feel, and begin courageous conversations about how emotions are shared within their relationship.

Erik van den Berg, CEO of Memo Therapeutics, shares his insights about leadership in biopharma and how Memo is working to develop antibodies to transform the lives of patients with viral infections and cancer.

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into some of the most significant shifts and strategies shaping our industry.Novartis's acquisition of Avidity Biosciences for a staggering $12 billion marks a pivotal moment in the pharmaceutical landscape this year. With this acquisition, Novartis underscores its commitment to bolstering its neuromuscular disease pipeline. Avidity Biosciences has made a name for itself with its cutting-edge RNA therapeutic technologies, particularly its Antibody Oligonucleotide Conjugates (AOCs). This platform uniquely combines monoclonal antibodies with oligonucleotides, enhancing precision in targeting specific cell types. The integration of Avidity's technology into Novartis's research efforts could accelerate the development of new therapies, potentially transforming patient care with more effective and targeted treatment options. This move not only highlights the industry's focus on specialized therapeutic areas but also anticipates future advances in RNA therapeutics, extending beyond neuromuscular disorders to areas like oncology.In a similar vein, the FDA has shown its willingness to reconsider drugs that previously faced setbacks. GSK's Blenrep has made a return to the U.S. market after receiving approval for treating certain myeloma patients. This approval is particularly noteworthy given the drug's earlier negative advisory committee vote and postponed decision. It marks a significant rebound for GSK's oncology portfolio and reflects the FDA's dynamic approach towards drugs that show potential in specific therapeutic combinations.Meanwhile, Sanofi continues to make waves with Dupixent, achieving over €4 billion in quarterly sales due to its expanded indications. This success contrasts with a decline in Sanofi's vaccine sales, demonstrating shifting dynamics within pharmaceutical portfolios where biologics and specialty drugs are increasingly pivotal. Sanofi's recent financial report highlighted a notable 17% drop in vaccine sales due to reduced demand and pricing challenges in Europe. In response, companies must navigate fluctuating public health demands and economic pressures effectively.On the global stage, efforts to make transformative therapies like Vertex's Trikafta more accessible are gaining momentum through innovative trade-policy workarounds. A buyers club aims to introduce a lower-cost alternative produced by Bangladesh's Beximco, highlighting ongoing challenges and creative strategies in global drug accessibility.Roche's expansion through Chugai's $200 million M&A deal for an IgA nephropathy asset underscores the strategic importance of regional markets in driving growth. Similarly, Lonza's acquisition of a California biologics site aligns with its goals to meet increasing biomanufacturing demands.The industry is also adapting to technological advancements, with AI integration into life sciences commercialization being touted as a frontier for growth. Despite this potential, many organizations remain unprepared to harness AI fully. Leading companies embedding AI solutions aim for measurable outcomes that could significantly drive strategic decision-making and operational efficiencies.Eli Lilly's acquisition of Adverum Biotechnologies aligns with its strategic interests in gene therapy, focusing on promising therapeutic programs that address unmet medical needs. This acquisition centers around Ixo-vec for wet age-related macular degeneration (AMD), highlighting broader industry trends towards investing heavily in innovative therapies that address unmet needs.Conversely, Sanofi's halt on an RSV vaccine development highlights the inherent risks in vaccine development pipelines. Meanwhile, Regeneron's decision to discontinue a CAR T candidate acquired from 2seventy bio showcases ongoing reassessment witSupport the show

In this episode of The Midweek Takeaway, Phil Carroll and Kevin Hornsby speak with Anthony Tennyson, CEO of Solvonis Therapeutics (LSE: SVNS), about the company's strengthened leadership following the appointment of Paul Carter, former Gilead CCO, and its progress across key CNS programmes. Anthony outlines Solvonis' licensing-first, capital-efficient model and updates on SVN-001 for alcohol use disorder, SVN-002 for the US market, and SVN-SDN-14 targeting PTSD — reflecting Solvonis' mission to advance next-generation treatments for addiction and mental health. Disclaimer & Declaration of Interest This podcast may contain paid promotions, including but not limited to sponsorships, endorsements, or affiliate partnerships. The information, investment views, and recommendations provided are for general informational purposes only and should not be construed as a solicitation to buy or sell any financial products related to the companies discussed. Any opinions or comments are made to the best of the knowledge and belief of the commentators; however, no responsibility is accepted for actions based on such opinions or comments. The commentators may or may not hold investments in the companies under discussion. Listeners are encouraged to perform their own research and consult with a licensed professional before making any financial decisions based on the content of this podcast. 

In this episode of “Answers From the Lab,” host Bobbi Pritt, M.D., chair of the Division of Clinical Microbiology at Mayo Clinic, is joined by William Morice II, M.D., Ph.D., CEO and president of Mayo Clinic Laboratories, to discuss recent news about drug-resistant infections. Later, Paul Jannetto, Ph.D., director of the Clinical and Forensic Toxicology Lab, Clinical Mass Spectrometry Lab, and Metals Lab, joins Dr. Pritt for the deep dive segment. Together, they explore how diagnostics are shaping the future of therapeutics.  New podcast format launch (00:25): Drs. Morice and Pritt introduce the exciting new format for “Answers From the Lab,” including the addition of in-depth expert segments.   Drug-resistant infections (02:05): Discover how clinical diagnostics play a critical role in combating the growing threat of antibiotic resistance. Diagnostics' role in advancing precision medicine (13:28): Learn how diagnostics, specifically drug monitoring, are advancing personalized therapies and contributing to better outcomes. Note: Information in this post was accurate at the time of its posting. Resources Therapeutics testing: A clear path to accurate answers Therapeutics testing at Mayo Clinic Laboratories WHO warns of widespread resistance to common antibiotics worldwide Tests for infectious disease detection and identification  Connect with Us Is there a question or topic you'd like us to explore in a future episode? Email us at mayocliniclabs@mayo.edu. Learn more about our hosts and guests and connect with them on social media.  Bobbi Pritt, M.D.  Bio  |  LinkedIn Bill Morice, M.D., Ph.D. Bio  |  LinkedIn Paul Jannetto, Ph.D. Bio  |  LinkedIn

Dr. Marc Salzberg, President, CEO, and Chief Medical Officer at Airway Therapeutics, is developing a drug AT-100 to prevent bronchopulmonary dysplasia (BPD) in preterm infants, a severe condition with no existing treatment. These infants are at high risk for BPD because of a low level of a protective protein that reduces inflammation and clears infections from their underdeveloped lungs. The drug's mechanism of action suggests it has potential for treating other inflammatory conditions such as asthma, COPD, and severe pneumonia. Marc explains, "We're focusing on developing drugs or interventions for severe respiratory conditions for prevention or treatment of severe respiratory conditions. And our first project is focusing on the respiratory condition that preterm neonates have, which is called bronchopulmonary dysplasia, and cannot be treated or prevented yet. It's a very severe condition. And that really triggered my interest in getting engaged because it's going to be a paradigm shift if we manage to bring this drug to market." "The protein that we're developing is an endogenous protein that we all have. In the past years or decade, it has been discovered that this protein has a very essential function in fighting inflammation and infection on a daily basis. Now, there are certain conditions or instances where the protein is low-functioning. For instance, in preterm-born babies, but also in adults with severe respiratory inflammation, with pneumonias, with asthma, or COPD. In all those cases where protein is low, those are the instances where you actually need it most. So, replacing it in those instances is a kind of logical rationale for the concept for the treatment that we're developing." #AirwayTherapeutics #BPD #InflammatoryDiseases #Zelpultidealfa #PrematureBabies #PretermBabies airwaytherapeutics.com Download the transcript here  

Dr. Marc Salzberg, President, CEO, and Chief Medical Officer at Airway Therapeutics, is developing a drug AT-100 to prevent bronchopulmonary dysplasia (BPD) in preterm infants, a severe condition with no existing treatment. These infants are at high risk for BPD because of a low level of a protective protein that reduces inflammation and clears infections from their underdeveloped lungs. The drug's mechanism of action suggests it has potential for treating other inflammatory conditions such as asthma, COPD, and severe pneumonia. Marc explains, "We're focusing on developing drugs or interventions for severe respiratory conditions for prevention or treatment of severe respiratory conditions. And our first project is focusing on the respiratory condition that preterm neonates have, which is called bronchopulmonary dysplasia, and cannot be treated or prevented yet. It's a very severe condition. And that really triggered my interest in getting engaged because it's going to be a paradigm shift if we manage to bring this drug to market." "The protein that we're developing is an endogenous protein that we all have. In the past years or decade, it has been discovered that this protein has a very essential function in fighting inflammation and infection on a daily basis. Now, there are certain conditions or instances where the protein is low-functioning. For instance, in preterm-born babies, but also in adults with severe respiratory inflammation, with pneumonias, with asthma, or COPD. In all those cases where protein is low, those are the instances where you actually need it most. So, replacing it in those instances is a kind of logical rationale for the concept for the treatment that we're developing." #AirwayTherapeutics #BPD #InflammatoryDiseases #Zelpultidealfa #PrematureBabies #PretermBabies airwaytherapeutics.com Listen to the podcast here  

Members of the Council on Therapeutics unpack two ASHP policies adopted in the 2025 House of Delegates— one addressing the FDA's proposal to change drug naming conventions, and the other requiring height and weight on certain medication orders. They share why these policies matter, the challenges encountered during the policy process, and the improvements they hope to see in patient care as a result. The information presented during the podcast reflects solely the opinions of the presenter. The information and materials are not, and are not intended as, a comprehensive source of drug information on this topic. The contents of the podcast have not been reviewed by ASHP, and should neither be interpreted as the official policies of ASHP, nor an endorsement of any product(s), nor should they be considered as a substitute for the professional judgment of the pharmacist or physician.

Professors Bas Bloem and Werner Poewe explore the underlying mechanisms of Parkinson's disease and discuss current and emerging therapeutic approaches. A clear and insightful conversation for anyone seeking to better understand the science behind PD and its treatment.

We love to hear from our listeners. Send us a message. In this week's episode of the Business of Biotech -- part two in a four-part series recorded in-person at Catalyst Pharmaceuticals' Miami headquarters -- we're speaking with Daniel Teper, an entrepreneur and most recently, founder and CEO at NAYA Therapeutics. Based in South Florida, NAYA is developing NK-engaging bifunctional antibodies and Astatine-211 radiopharmaceuticals targeting hepatocellular carcinoma. Daniel discusses the company's decentralized manufacturing strategy, the current funding climate for early-stage companies, his plan to conduct clinical trials in China, and what's unique about the South Florida life sciences ecosystem.  Access this and hundreds of episodes of the Business of Biotech videocast under the Business of Biotech tab at lifescienceleader.com. Subscribe to our monthly Business of Biotech newsletter. Get in touch with guest and topic suggestions: ben.comer@lifescienceleader.comFind Ben Comer on LinkedIn: https://www.linkedin.com/in/bencomer/

Summary del Show: • Wall Street opera mixto a la espera de declaraciones de Jerome Powell en plena parálisis del gobierno. • EE.UU. aprueba exportaciones de chips de $NVDA hacia Emiratos Árabes como parte de un plan de $1.4T. • La alemana n8n, respaldada por $NVDA, alcanza valoración de $2.5B en ronda Serie C. • Novo Nordisk $NVO adquiere Akero Therapeutics $AKRO por hasta $5.2B.

On September 24, 2025, Hoth Therapeutics (NASDAQ: HOTH) announced the expansion of its intellectual property portfolio for HT-001, a topical therapeutic for chemotherapy-induced rash.CEO Robb Knie discusses the development and potential of HT-001, along with other updates, including the oncology drug HT-KIT, our obesity initiative in partnership with the U.S. Department of Veterans Affairs, and more.Learn more about the company: https://hoththerapeutics.com/Watch the full YouTube interview here: https://youtu.be/99FydlxXwa8?si=uEm_KLqaggTfQSI8And follow us to stay updated: https://www.youtube.com/@GlobalOneMedia?sub_confirmation=1

With cannabis products popping up everywhere—from wellness aisles to dispensaries—there's still a lot of confusion around what's legal, what's safe, and what actually works. There's a lot of confusion surrounding cannabis, hemp, THC, and their role in health — especially as more patients explore alternative treatments for anxiety, chronic pain, and neurological conditions. Dr. Leigh Vinocur - emergency physician, national media medical expert, and one of the first graduates from the University of Maryland's groundbreaking master's program in Medical Cannabis Science and Therapeutics - is here to help clear things up. Dr. Leigh's new book, Never Let Them See You Sweat: How Science Can Help Us Harness Stress for Success (Bloomsbury, June 2025), explores how stress, mental health, and the body's endocannabinoid system are more connected than we ever knew — and how plant-based medicine, including cannabis, may play a vital role in future treatment protocols.

Biotech might produce the world's next trillion-dollar company—and Simba Gill and Steve Ledger are betting on it. Join Jess Larsen as he explores how Serina Therapeutics' drug optimization platform could reshape the future of treatment for Parkinson's, cancer, and beyond. Simba, with four decades of biotech leadership, and Steve, with roots in finance and venture, share how science, capital, and mission come together to drive massive impact. This is a behind-the-scenes look at what happens when breakthrough science collides with visionary leadership. Learn more about your ad choices. Visit megaphone.fm/adchoices

In this episode, Jacob sits down with Joshua Meier, co-founder of Chai Discovery and former Chief AI Officer at Absci, to explore the breakthrough moment happening in AI drug discovery. They discuss how the field has evolved through three distinct waves, with the current generation of companies finally achieving success rates that seemed impossible just years ago.  The conversation covers everything from moving drug discovery out of the lab and into computers, to why AI models think differently than human chemists, to the strategic decisions around open sourcing foundational models while keeping design capabilities proprietary. It's an in-depth look at how AI is fundamentally changing pharmaceutical innovation and what it means for the future of medicine. Check out the full Chai-2 Zero-Shot Antibody report linked here: https://www.biorxiv.org/content/10.1101/2025.07.05.663018v1.full.pdf (0:00) Intro(1:25) The Evolution of AI in Drug Discovery(5:14) Current State and Future of AI in Biotech(10:08) Challenges and Modalities in Therapeutics(14:44) Data Generation and Model Training(22:52) Open Source and Model Development at Chai(29:52) Open Source Models and Their Impact(34:36) How Should Chai-2 Be Used?(38:53) The Future of AI in Pharma and Biotech(42:46) Key Milestones and Metrics in AI-Driven Drug Discovery(47:20) Critiques and Hesitation(54:01) Quickfire Out-Of-Pocket: https://www.outofpocket.health/

What if a drug could help chemotherapy patients continue treatment without painful side effects? Hoth Therapeutics (NASDAQ: HOTH) is making that possible by developing innovative treatments that address unmet medical needs and help patients maintain their therapy safely.In this interview, CEO Robb Knie discusses HT001, the company's lead drug currently in Phase 2 trials for chemotherapy-induced rash, and HTKIT, which shows promise in cancer treatment. He also shares how the company is advancing programs for Alzheimer's and obesity, including an obesity drug licensed from the U.S. Department of Veterans Affairs.With a diversified pipeline, a patient-focused approach, and strategic use of AI to de-risk and accelerate development, Hoth Therapeutics is positioning itself as a biotech company to watch.Learn more about Hoth Therapeutics: https://hoththerapeutics.comWatch the full YouTube interview here: https://youtu.be/AYQa3g6dVLA?si=w_zDH0TaSxP3m6JiAnd follow us to stay updated: https://www.youtube.com/@GlobalOneMedia?sub_confirmation=1

On August 5, Health Secretary Robert F. Kennedy Jr. announced that the Department of Health and Human Services would terminate almost $500 million in mRNA vaccine development grants and contracts, affecting 22 projects. Biologist and mRNA researcher Jeff Coller joins Host Ira Flatow to talk about what this move means for future mRNA research in the US beyond these immediate projects.Plus, reporter Casey Crownhart joins Ira to discuss the latest in climate news, including flooding in Juneau, Alaska; how Ford is pursuing further electric vehicle manufacturing despite federal roadblocks; and a startup using Earth itself as a giant battery.Guests:Dr. Jeff Coller is the Bloomberg Distinguished Professor of RNA Biology and Therapeutics at Johns Hopkins University.Casey Crownhart is a senior climate reporter for MIT Technology Review in New York, New York.Transcripts for each episode are available within 1-3 days at sciencefriday.com. Subscribe to this podcast. Plus, to stay updated on all things science, sign up for Science Friday's newsletters.

In this Huberman Lab Essentials episode, my guest is Dr. Matthew Johnson, PhD, a senior researcher for the Center of Excellence for Psilocybin Research and Treatment at Sheppard Pratt's Institute for Advanced Diagnostics and Therapeutics. We explore the science and therapeutic potential of psychedelic medicine, including psilocybin, MDMA and LSD. We discuss how these substances can profoundly alter perception and self-identity, providing long-lasting relief from depression, addiction and trauma when used in controlled clinical settings. We also discuss microdosing and emerging research on psychedelics' potential to support recovery from neurological injuries. Read the episode show notes at hubermanlab.com. Thank you to our sponsors AG1: https://drinkag1.com/huberman David: https://davidprotein.com/huberman BetterHelp: https://betterhelp.com/huberman Timestamps 00:00:00 Matthew Johnson; Psychedelics 00:01:44 Different Classes of Psychedelics 00:04:33 Psychedelics & Altering Models 00:06:18 Sponsor: David 00:07:33 LSD, Psylocibin & Serotonin 00:09:55 Psychedelic Clinical Trials 00:13:40 Therapy, Trust, Psychedelics 00:16:47 Letting Go & Psychedelic Experience, Self-Representation, Lasting Changes 00:22:31 Sponsors: AG1 & BetterHelp 00:25:26 MDMA, Dopamine & Serotonin; Bad Trips & Transcendental Experience 00:28:49 Dangers of Psychedelics 00:31:11 Microdosing Psychedelics, Antidepressant 00:35:27 Head Injuries, Psychedelics, Depression 00:38:29 Acknowledgements Disclaimer & Disclosures Learn more about your ad choices. Visit megaphone.fm/adchoices